Karyopharm Therapeutics Inc. (KPTI) Trading Up 2.1%
Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) were up 2.1% on Wednesday . The company traded as high as $9.48 and last traded at $9.16, with a volume of 1,085,680 shares changing hands. The stock had previously closed at $8.97.
A number of analysts recently weighed in on KPTI shares. Robert W. Baird started coverage on Karyopharm Therapeutics in a report on Monday, June 27th. They issued an “outperform” rating and a $16.00 price objective for the company. Canaccord Genuity set a $20.00 price objective on Karyopharm Therapeutics and gave the company a “buy” rating in a report on Saturday, August 6th. Zacks Investment Research downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 9th. Wedbush restated an “outperform” rating and issued a $14.00 price objective on shares of Karyopharm Therapeutics in a report on Friday, June 10th. Finally, HC Wainwright started coverage on Karyopharm Therapeutics in a report on Thursday, August 18th. They issued a “buy” rating and a $15.00 price objective for the company. Two analysts have rated the stock with a sell rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $15.97.
The stock’s market capitalization is $328.94 million. The company’s 50 day moving average is $7.60 and its 200 day moving average is $8.07.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/07/karyopharm-therapeutics-inc-kpti-trading-up-2-1.html
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by $0.08. Analysts anticipate that Karyopharm Therapeutics Inc. will post ($3.22) earnings per share for the current year.
In other Karyopharm Therapeutics news, major shareholder Ltd Chione sold 45,541 shares of the business’s stock in a transaction on Thursday, June 9th. The shares were sold at an average price of $9.21, for a total value of $419,432.61. Following the completion of the sale, the insider now directly owns 8,605,818 shares of the company’s stock, valued at $79,259,583.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 14.79% of the company’s stock.
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.